Low Dose Naltrexone in Dermatology

Joanna Jaros, Peter A Lio

Research output: Contribution to journalArticle

Abstract

Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide range of conditions including Crohn’s disease, fibromyalgia, major depressive disorder, cancer, chronic regional pain syndrome, Charcot-Marie-Tooth, and multiple sclerosis.1-5 Recently, off label LDN has been shown to improve dermatologic conditions such as systemic sclerosis, Hailey-Hailey Disease, lichen planopilaris, and guttate psoriasis.6-9 In this article, we examine the existing evidence for use of LDN in skin disease and discuss its potential application in the treatment of atopic dermatitis (AD). J Drugs Dermatol. 2019;18(3):235-238.

Original languageEnglish (US)
Pages (from-to)235-238
Number of pages4
JournalJournal of drugs in dermatology : JDD
Volume18
Issue number3
StatePublished - Mar 1 2019

Fingerprint

Naltrexone
Dermatology
Benign Familial Pemphigus
Charcot-Marie-Tooth Disease
Lichens
Fibromyalgia
Systemic Scleroderma
Major Depressive Disorder
Atopic Dermatitis
Skin Diseases
Crohn Disease
Chronic Pain
Anti-Inflammatory Agents
Therapeutics
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Dermatology

Cite this

Jaros, Joanna ; Lio, Peter A. / Low Dose Naltrexone in Dermatology. In: Journal of drugs in dermatology : JDD. 2019 ; Vol. 18, No. 3. pp. 235-238.
@article{d606a07eddca44619cfa2afb1680d32e,
title = "Low Dose Naltrexone in Dermatology",
abstract = "Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide range of conditions including Crohn’s disease, fibromyalgia, major depressive disorder, cancer, chronic regional pain syndrome, Charcot-Marie-Tooth, and multiple sclerosis.1-5 Recently, off label LDN has been shown to improve dermatologic conditions such as systemic sclerosis, Hailey-Hailey Disease, lichen planopilaris, and guttate psoriasis.6-9 In this article, we examine the existing evidence for use of LDN in skin disease and discuss its potential application in the treatment of atopic dermatitis (AD). J Drugs Dermatol. 2019;18(3):235-238.",
author = "Joanna Jaros and Lio, {Peter A}",
year = "2019",
month = "3",
day = "1",
language = "English (US)",
volume = "18",
pages = "235--238",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "3",

}

Low Dose Naltrexone in Dermatology. / Jaros, Joanna; Lio, Peter A.

In: Journal of drugs in dermatology : JDD, Vol. 18, No. 3, 01.03.2019, p. 235-238.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Low Dose Naltrexone in Dermatology

AU - Jaros, Joanna

AU - Lio, Peter A

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide range of conditions including Crohn’s disease, fibromyalgia, major depressive disorder, cancer, chronic regional pain syndrome, Charcot-Marie-Tooth, and multiple sclerosis.1-5 Recently, off label LDN has been shown to improve dermatologic conditions such as systemic sclerosis, Hailey-Hailey Disease, lichen planopilaris, and guttate psoriasis.6-9 In this article, we examine the existing evidence for use of LDN in skin disease and discuss its potential application in the treatment of atopic dermatitis (AD). J Drugs Dermatol. 2019;18(3):235-238.

AB - Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide range of conditions including Crohn’s disease, fibromyalgia, major depressive disorder, cancer, chronic regional pain syndrome, Charcot-Marie-Tooth, and multiple sclerosis.1-5 Recently, off label LDN has been shown to improve dermatologic conditions such as systemic sclerosis, Hailey-Hailey Disease, lichen planopilaris, and guttate psoriasis.6-9 In this article, we examine the existing evidence for use of LDN in skin disease and discuss its potential application in the treatment of atopic dermatitis (AD). J Drugs Dermatol. 2019;18(3):235-238.

UR - http://www.scopus.com/inward/record.url?scp=85063798685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063798685&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 235

EP - 238

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 3

ER -